On the tail of rumors that Merck & Co. Inc. and others holding stakes in Personalis Inc. might take over the firm, Chicago-based Tempus AI Inc. ended speculation by disclosing its plan to buy the ...

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In preclinical models of HER2 and EGFR co ...

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in ...

*For more details about COVID-19 therapeutics and vaccines, diagnostic products and clinical trial delays, go to BioWorld Snapshots.

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head ...

Published August 2019 Deals analysis Transforming R&D and health care with artificial intelligence Biopharmas move into deep waters of massive data, high R&D potential AI propels med tech into new ...

Newronika SpA received CE mark certification for its latest adaptive deep brain stimulation (aDBS) system, which includes the ...

Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s ...

The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid ...

GSK plc is halting work with camlipixant, a P2X3 receptor antagonist, in adults with refractory chronic cough (RCC) after reporting mixed results from the Calm-1 and Calm-2 phase III trials. The first ...

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical ...

What does med tech in 2026 look like? Uncertainty remains. Global investors are confident about exit opportunities in the year ahead. But financing will be targeted. For the med-tech companies, ...